Content area

|
|

SGLT2-hæmmere til type 1-diabetes

Forfatter(e)

Elisabeth Buur Stougaard1, Hanan Amadid1, Esben Søndergaard2, Marit Eika Jørgensen1, 3, Frederik Persson1 & Peter Rossing1, 4

1) Steno Diabetes Center Copenhagen, 2) Steno Diabetes Center Aarhus, 3) Statens Institut for Folkesundhed, Syddansk Universitet, 4) Institut for Klinisk Medicin, Det Sundhedsvidenskabelige Fakultet, Københavns Universitet

Ugeskr Læger 2020;182:V05200351

Reference: 
Ugeskr Læger 2020;182:V05200351
Blad nummer: 
SGLT 2 inhibitors in Type 1 diabetes

Elisabeth Buur Stougaard, Hanan Amadid, Esben Søndergaard, Marit Eika Jørgensen, Frederik Persson & Peter Rossing

Ugeskr Læger 2020;182:V05200351

The sodium-glucose cotransporter 2 inhibitor (SGLT2i) dapagliflozin has been approved for the treatment of Type 1 diabetes (T1D) with significant reductions in HbA1c, weight, total daily insulin dose and significant increase in time in range without an increased risk of hypoglycaemia. The use of SGLT2i in T1D has, however, shown a significant increase from 1,9% to 4,0% in the risk of diabetic ketoacidosis (DKA), which may present as euglycaemic DKA. In this review we therefore find it important to know, that DKA may present with normal/near-normal blood glucose levels, if the patient is treated with an SGLT2i.

Du skal være logget ind for at læse denne artikel
Log ind

Right side